Men’s health is in the news and we’re proud to be in the forefront.

Clarus Therapeutics Presents Positive Safety and Efficacy Data for Jatenzo^® (testosterone undecanoate) Oral Capsules, CIII at ENDO 2021, the Endocrine Society’s Annual Meeting

March 20, 2021

Clarus Therapeutics Appoints Richard ‘Ric’ Peterson as Chief Financial Officer

February 24, 2021

Clarus Announces JATENZO® (testosterone undecanoate) Capsules, CIII now Covered by Express Scripts

December 7, 2020

Clarus Therapeutics Announces Financing to Support the Commercial Launch and Availability of JATENZO® (testosterone undecanoate) Capsules, CIII for the Treatment of Hypogonadism

March 16, 2020

Upcoming Events

Past Events

Request online access to a reprint from Therapeutic Advances in Urology, provided to you by the Medical Affairs team at Clarus Therapeutics, Inc.

June 30, 2020

Read more from The Journal of Clinical Endocrinology & Metabolism about hypogonadal men who were able to find relief.

May 8, 2020

Please see the full Prescribing Information for JATENZO, including BOXED WARNING on increases in blood pressure.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

JATENZO^® is a registered trademark of Clarus Therapeutics, Inc.